Celcuity Stock

Celcuity EV/EBIT

The EV/EBIT (Enterprise Value to EBIT) of Celcuity (CELC) as of Aug 2, 2026 is -30.36. In the previous year, EV/EBIT (Enterprise Value to EBIT) was -46.16 — a change of -34.22% (higher).

EV/EBIT

-30.36

YoY

-34.22%

Last updated:

EV/EBIT (Enterprise Value to EBIT) of Celcuity is 2026 -30.36 . EV/EBIT (Enterprise Value to EBIT) of Celcuity was 2025 -46.16 . It decreases by -34.22% higher compared to the previous year.

The Celcuity EV/EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

PRICE-TO-EBIT
Date
PRICE-TO-EBIT
Jan 1, 2019
-13.97 base
Jan 1, 2020
-9.85 base
Jan 1, 2021
-6.94 base
Jan 1, 2022
-6.00 base
Jan 1, 2023
-6.36 base
Jan 1, 2024
-4.95 base
Jan 1, 2025
-30.43 base
Jan 1, 2026 (e)
-21.23 base
YEARPRICE-TO-EBIT
2026 est -21.23
2025 -30.43
2024 -4.95
2023 -6.36
2022 -6.00
2021 -6.94
2020 -9.85
2019 -13.97
2018 -30.73
2017 -32.09
2016 -
2015 -
Access this data via the Eulerpool API

Celcuity Valuation

Details

Historical Valuation Multiples

Price-to-Earnings Ratio (P/E)

The P/E ratio divides Celcuity's share price by its earnings per share. It tells you how many years of current earnings you are "paying for" when you buy the stock. A P/E of 20 means you pay $20 for every $1 of annual earnings. The S&P 500 historically trades at an average P/E of roughly 15–17. A P/E significantly above that may signal high growth expectations; one below may indicate undervaluation — or declining business quality.

Price-to-Sales Ratio (P/S)

The P/S ratio divides market capitalization by total revenue. Unlike the P/E ratio, it works even for companies that are not yet profitable, making it essential for evaluating high-growth firms. A P/S below 1.0 may indicate undervaluation, while ratios above 10 are typically reserved for fast-growing tech or SaaS companies with high expected future margins.

Price-to-EBIT Ratio

This ratio relates Celcuity's market price to its operating earnings, excluding the effects of debt structure and tax jurisdiction. It is particularly useful for comparing companies across different countries or with different levels of leverage, because it focuses purely on operational profitability. Lower values suggest cheaper operational earnings.

How to Use This Chart

This chart plots Celcuity's valuation multiples over time. Compare the current P/E, P/S, and P/EBIT to their own historical averages — if the current ratio is well below the multi-year average, the stock may be relatively cheap compared to its own track record. Combine this with industry comparisons: a P/E that looks high in absolute terms may be justified if Celcuity grows earnings faster than its peers.

Celcuity Stock analysis

What does Celcuity do? Celcuity Inc is a biotechnology company founded by Brian Sullivan in 2012. The company is headquartered in Minneapolis, USA. The business model of Celcuity is based on researching and developing new diagnostic and treatment methods for various types of cancer. The company utilizes a proprietary technology platform called CELx, which enables the analysis of cancer cell signaling pathways and the development of individualized treatment strategies. Celcuity specializes in the development of diagnostics and personalized therapies based on individual cancer cell signaling pathways. The company operates in two divisions: 1. Diagnostics division: Celcuity's diagnostics division focuses on identifying new cancer markers and biomarkers for early detection of cancer and the development of individualized treatment strategies. 2. Therapy division: Celcuity's therapy division specializes in the development of personalized therapies based on individual cancer cell signaling pathways. Celcuity currently offers two products based on the CELx technology platform: 1. CELx HUB: CELx HUB is a cloud-based software that allows doctors and researchers to analyze cancer samples and develop individualized treatment strategies. 2. CELx TIL: CELx TIL is a diagnostic tool that measures the presence of tumor cells in the immune system of cancer patients. In summary, Celcuity Inc is a leader in the field of personalized cancer therapy based on individual cancer cell signaling pathways. The company has found a niche in this growing market and has a unique technology platform that allows it to serve its customers effectively. With its products and services, Celcuity is helping to revolutionize cancer treatment and improve the quality of life for cancer patients worldwide. Celcuity is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Celcuity stock

EV/EBIT (Enterprise Value to EBIT) of Celcuity is -30.36 in 2026.

Access this data via the Eulerpool API

Valuation — Celcuity

All Key Metrics — Celcuity